Krystal Biotech (KRYS) Change in Account Payables (2016 - 2026)

Krystal Biotech has disclosed Change in Account Payables across 11 years of filings, most recently posting $1.0 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $1.0 million, up 12.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $942000.0 (down 20.84% YoY), and the FY2025 annual result was $826000.0, down 18.3% from the prior year.
• Change in Account Payables came in at $1.0 million for Q1 2026 at Krystal Biotech, up from -$183000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $4.1 million in Q2 2025 to a low of -$4.0 million in Q3 2025.
• The 5-year median for Change in Account Payables is $91000.0 (2024), against an average of $88470.6.
• Across the five-year window, Change in Account Payables jumped 579.44% in 2024 and plunged 4517.58% in 2025, its largest moves.
• Krystal Biotech's Change in Account Payables stood at -$938000.0 in 2022, then surged by 76.33% to -$222000.0 in 2023, then sank by 166.22% to -$591000.0 in 2024, then soared by 69.04% to -$183000.0 in 2025, then soared by 658.47% to $1.0 million in 2026.
• The last three Change in Account Payables figures came in at $1.0 million (Q1 2026), -$183000.0 (Q4 2025), and -$4.0 million (Q3 2025), per Business Quant data.